<div id="readability-page-1"><p>GWN Securities Inc. lessened its holdings in shares of  Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 51.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,658 shares of the company's stock after selling 27,326 shares during the period. Johnson &amp; Johnson makes up  about  1.1% of GWN Securities Inc.'s portfolio, making the stock its 14th biggest holding. GWN Securities Inc.'s holdings in Johnson &amp; Johnson were worth $4,790,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>This ETF Is Proof That the Healthcare Rebound Is Real</li></ul><p>Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in  Johnson &amp; Johnson by 1.3% in the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company's stock worth $36,209,060,000 after acquiring an additional 3,085,180 shares in the last quarter.  Geode Capital Management LLC raised its position in shares of  Johnson &amp; Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company's stock valued at $9,227,988,000 after purchasing an additional 1,225,676 shares during the last quarter.  Norges Bank acquired a new stake in  Johnson &amp; Johnson in the 2nd quarter worth approximately $4,877,174,000.  Bank of New York Mellon Corp boosted its stake in  Johnson &amp; Johnson by 2.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company's stock worth $3,635,832,000 after purchasing an additional 620,039 shares in the last quarter.  Finally, Charles Schwab Investment Management Inc. grew its position in  Johnson &amp; Johnson by 0.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company's stock worth $2,894,979,000 after purchasing an additional 52,074 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several equities research analysts have recently commented on JNJ shares. BMO Capital Markets  reiterated an &#34;outperform&#34; rating on shares of Johnson &amp; Johnson in a research note on Thursday, December 11th. Stifel Nicolaus raised their target price on Johnson &amp; Johnson from $165.00 to $190.00 and gave the stock a &#34;hold&#34; rating in a research note on Wednesday, October 15th. UBS Group  reaffirmed a &#34;buy&#34; rating on shares of Johnson &amp; Johnson in a research report on Monday, January 5th. Royal Bank Of Canada  set a $240.00 price objective on Johnson &amp; Johnson in a report on Wednesday, December 17th. Finally, Morgan Stanley lifted their target price on Johnson &amp; Johnson from $190.00 to $197.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, December 12th. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned  a Buy rating and nine have issued  a Hold rating to the company. Based on data from MarketBeat, Johnson &amp; Johnson currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $213.33.</p><ul><li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li></ul><p><b>Check Out Our Latest Stock Report on JNJ</b></p><h2>Johnson &amp; Johnson Stock Performance</h2><p>NYSE JNJ opened at $218.81 on Friday. The firm has a market capitalization of $527.18 billion, a P/E ratio of 21.12, a PEG ratio of 2.26 and a beta of 0.34. The stock has a 50-day simple moving average of $205.82 and a two-hundred day simple moving average of $186.74. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson &amp; Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $220.11. </p><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 14th. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.76 by $0.04. The firm had revenue of $23.99 billion for the quarter, compared to analyst estimates of $23.73 billion. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%.Johnson &amp; Johnson's revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period last year, the company earned $2.42 earnings per share.  On average, equities analysts forecast that  Johnson &amp; Johnson will post 10.58 earnings per share for the current year. </p><h2>Johnson &amp; Johnson Dividend Announcement</h2><p>The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, February 24th. Johnson &amp; Johnson's dividend payout ratio  is currently 50.19%. </p><h2>About Johnson &amp; Johnson</h2> (Free Report)<p>Johnson &amp; Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.  </p><p>The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>Executive Order 14330: Trump’s Biggest Yet</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li></ul><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>GWN Securities Inc. reduced its holdings in Johnson & Johnson (NYSE: JNJ) by 51.6% in Q3, now owning 25,658 shares valued at $4.79 million. Other institutional investors like Vanguard and Geode Capital have increased their stakes. Analysts maintain a consensus rating of "Moderate Buy" with an average price target of $213.33. Johnson & Johnson's stock opened at $218.81, with a market cap of $527.18 billion and a recent EPS of $2.80, exceeding estimates. The company reported a revenue increase of 6.8% year-over-year.</p>

Johnson & Johnson $JNJ Shares Sold by GWN Securities Inc.